Newsroom
Latest News
News
Sera Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10
Salt Lake City, May 2, 2022 —Sera Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,…
News
SERA ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA BOARD
Sera announced that Dr. Jane F. Barlow has joined the Sera Board of Directors.
News
Sera Reports Fourth Quarter 2021 Financial Results
Salt Lake City – March 29, 2022 – Sera Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors…
News
Sera Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting
Salt Lake City, March 18, 2022 —Sera Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today presented data…
News
Sera To Present At Upcoming March Investor Conferences
Salt Lake City – March 3, 2022 – Sera Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced that…
News
Sera Presentation Rescheduled For Citi 2022 Healthcare Conference
Salt Lake City – February 17, 2022 – Sera Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced that…
News
Sera To Present At Upcoming February Investor Conferences
Salt Lake City – February 7, 2022 – Sera Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced that…
News
Sera Announces New Agreement With Multiplan, Expanding Patient Access To The PreTRM® Test
Feb 1, 2022, Sera announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks.
News
Sera Added To Nasdaq Biotechnology Index
Dec 15, Sera announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).
News
Sera Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth
Dec. 2, 2021, Sera announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® Test.